Xu Xiao Xuan, Wu Ya Jun, Wu Hong Yun, Hu Yu Xiang, Cheng Yi, Yan Li, Rao Jie, Wu Na, Wu Xiao Rong
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China.
Department of Ophthalmology,Ganzhou People's Hospital,Ganzhou,Jiangxi 341000,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Apr 28;41(2):261-266. doi: 10.3881/j.issn.1000-503X.10868.
Retinopathy of prematurity(ROP)is a pathological neovascularization with fibrotic changes in the fundus of premature infants.It is a major cause of preventable blindness in children in both developing and developed countries.Treatment of ROP has long been a hot research topic in ophthalmology and pediatrics.With a clearer knowledge of the pathogenesis of ROP,more basic and clinical studies have been carried out.The anti-vascular endothelial growth factor therapy and surgical treatment have become mature strategies,and a variety of therapeutic drugs including insulin-like growth factor-1,transforming growth factor-β,polyunsaturated fatty acids,and β-adrenergic receptor blockers have been developed.This article reviews the recent advances in ROP.
早产儿视网膜病变（ROP）是一种发生于早产儿眼底的伴有纤维化改变的病理性新生血管形成。它是发展中国家和发达国家儿童可预防性失明的主要原因。ROP的治疗长期以来一直是眼科和儿科学领域的研究热点。随着对ROP发病机制的认识更加清晰，开展了更多的基础和临床研究。抗血管内皮生长因子疗法和手术治疗已成为成熟的治疗策略，并且已经研发出多种治疗药物，包括胰岛素样生长因子-1、转化生长因子-β、多不饱和脂肪酸和β-肾上腺素能受体阻滞剂。本文综述了ROP的最新研究进展。
